Waters has announced the completion of its acquisition of BD’s Biosciences and Diagnostic Solutions businesses.
The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...
Q4 2025 earnings call recap: clonoSEQ MRD growth, 2026 revenue guidance, margins, cash burn and risks—read now.
Turning to the acquired business contribution, following today's expected close of the transaction, we expect the Biosciences ...
Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals. Under this framework, MRD negativity is ...
A new study may change the way scientists think about the distance traveled by tiny bubbles carrying signals between cells ...
FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.
Q4 2025 Earnings Call February 9, 2026 8:30 AM ESTCompany ParticipantsCaspar Tudor - Head of Investor RelationsUdit Batra ...
The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...
Multiple sclerosis B-cell profiles differ by ancestry and sex among Black and Hispanic patients with multiple sclerosis.
Waters Corporation (NYSE: WAT) ("Waters") today announced it has completed the previously announced combination with the ...
Waters Corporation (NYSE:WAT) Q4 2025 Earnings Call Transcript February 9, 2026 Waters Corporation beats earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results